References
- Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, et al. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol 2021; 45: 101460. doi: 10.1016/j. clinre.2020.05.008
- Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018; 67: 401-21. doi: 10.1002/hep.29487
- Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016; 36: 166-76. doi: 10.1111/liv.12965
- Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 2017; 19: 40. doi: 10.1007/s11912-017-0597-2
- Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155-66. doi: 10.1111/liv.12818
- de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 2016; 39: 334-43. doi: 10.1007/s00270-015-1208-y
- Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) study. Oncol Res 2020; 28: 75-94. doi: 10.3727/096504019x15662966719585
- Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, et al. The comprehensive analysis of efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple-center, cohort study. Oncol Res 2020; 28: 249-71. doi: 10.3727/096504019x15766663541105
- Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, et al. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis. Clin Res Hepatol Gas 2022; 46: 101893. doi: 10.1016/j. clinre.2022.101893
- Wu B, Zhou J, Ling G, Zhu D, Long Q. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol 2018; 16: 69. doi: 10.1186/s12957-018-1368-8
- Ma Y, Zhao C, Zhao H, Li H, Chen C, Xiang H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res 2019; 11: 7456-70. PMID: 31934293
- Duan XH, Ju SG, Han XW, Ren JZ, Li FY, Chen PF, et al. Arsenic trioxideeluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur Rev Med Pharmaco 2020; 24: 1468-80. doi: 10.26355/eurrev_202002_20206
- Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat 2019; 18: 1533033819830751. doi: 10.1177/1533033819830751
- Liang B, Xiang H, Ma C, Xiong B, Ma Y, Zhao C, et al. Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res 2020; 12: 941-56. doi: 10.2147/cmar.S187203
- Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, et al. Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: Multicenter study. AJR Am J Roentgenol 2021; 217: 933-43. doi: 10.2214/ajr.20.24708
- Zhang S, Huang C, Li Z, Yang Y, Bao T, Chen H, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers. Drug Deliv 2017; 24: 1011-7. doi: 10.1080/10717544.2017.1344336
- Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol 2018; 24: 161-9. doi: 10.3748/wjg.v24.i2.161
- Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 2019; 72: 28-36. doi: 10.1016/j.ctrv.2018.11.002
- Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma 2019; 6: 105-17. doi: 10.2147/jhc.S168682
- Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis. Front Oncol 2021; 11: 576232. doi: 10.3389/fonc.2021.576232
- Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 2018; 18: 124. doi: 10.1186/s12876-018-0848-1
- Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-50. doi: 10.1016/j.jhep.2012.07.017
- Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, Morosi C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gadtroen Hepatol 2016; 31: 645-53. doi: 10.1111/jgh.13147
- Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465. doi: 10.1186/s12885-015-1480-x
- Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2014; 20: 17206-17. doi: 10.3748/wjg.v20.i45.17206